The LiverTox database (https ://liver tox.nlm.nih.gov/index.html) provides accessible information about the hepatotoxicity, mechanisms, clinical manifestation, outcomes and management of drug-induced liver injury (DILI). 1 DILI is difficult to diagnose and is becoming an interesting topic involving prescription and nonprescription medications, biological agents, Chinese herbs and extracts and dietary supplements. [2] [3] [4] [5] [6] Fenofibrate is a fibric acid derivative that has been widely used to clinically treat hypertriglyceridemia and dyslipidemia in patients for two decades. DILI associated with fenofibrate occurs very rarely (only 0.6% of patients). 7 In this paper, we present a special case of acute severe hepatocellular injury that is highly likely induced by fenofibrate after therapy for a short period of time in a patient without primary or secondary liver disease.
8 years. He was diagnosed with hypertriglyceridemia 2 years ago and took Rosuvastatin calcium for 1 month, which was ceased after hospital discharge. He had not been treated with fenofibrate since the diagnosis of hypertriglyceridemia, and there was no allergic history to any drug or food. A complete ultrasound of the abdomen was normal.
During the medical treatment period in our hospital, we continued administration of the previous hypoglycaemic agents (insulin aspart 50 injection, metformin hydrochloride sustained release tablets 500 mg orally b.i.d. and acarbose 50 mg orally t.i.d.). On admission, he did not feel chest distress and ceased his therapy with the suxiao jiuxin pill, which has been widely used to treat coronary heart disease without significant adverse reactions in China. 8 The patient's laboratory results at the time of presentation are shown in Table 1 . His laboratory values revealed apparent hypertriglyceridemia (6.74 mmol/L) on 24 May, so he started taking fenofibrate at a regular dose of 200 mg once daily to decrease the risk of pancreatitis and cardiovascular disease. [9] [10] [11] Before beginning fenofibrate treatment, he had normal serum liver enzymes and bilirubin. There was no family history of liver disease. On the morning of 26 May, metformin was added at a dose of 500 mg t.i.d. due to a high glucose level.
Then, the patient felt epigastric pain, precordial pain and nausea. To exclude acute ischaemic cardiovascular events and other diseases, we conducted an electrocardiogram (ECG) and tested for myohemoglobin (MB), troponin I (TnI), creatine kinase isoenzymes (CK-MB), ketone, amylopsin and creatinine, but these tests were all normal. 
TA B L E 1 The changes in laboratory values during hospitalization

F I G U R E 1 Utilization of drugs and hepatic enzymes changes during hospitalization
Adenosine cyclophosphate and pantoprazole sodium injection were administered to alleviate the symptoms. The pain was relieved but relapsed after breakfast. To rule out the suspicion of metformin, we stopped using metformin the same day and tested the ECG, MB, TnI and CK-MB another day, but there were no abnormal findings. On 28
May, when the patient complained of epigastric discomfort and fatigue, liver enzymes were tested and found to be obviously elevated ( Figure 1 ).
Upon admission, the patient showed normal hepatic enzymes, and there was no previously known liver disease or alcoholism history. The patient was found to be free of autoimmune hepatitis, viral Fenofibrate is a fibric acid derivative that is well tolerated and used mainly to treat hypertriglyceridemia and hypercholesterolaemia for cardioprotection. [13] [14] [15] [16] A dose of 43 to 130 mg orally once daily is the initial dose in adults and can be adjusted to 300 mg after dinner once daily according to the manufacturer's instructions. The common adverse effects of fenofibrate reported in liver injury patients include gastrointestinal upset, rash, myopathy, fever, rhabdomyolysis and renal failure [17] [18] [19] [20] [21] [22] [23] ; acute DILI induced by fenofibrate is rare (0.6%) and usually asymptomatic, transient and mild, but a very severe case could result in liver transplantation treatment or death. 7, 17, 18, 20 The latency to onset is variable, ranging from 2 weeks to even 2 years of fenofibrate treatment. 1, 7, 24 We reported that the epigastric pain of the patient occurred only after taking fenofibrate for 2 days, and this pain may be an early symptom associated with the onset of acute ischaemic cardiovascular events or the side effect of metformin. Of course, it is difficult to differentiate whether this condition is a side effect of metformin or an early clinical manifestation of hepatitis. However, the hepatic enzymes of the patient were associated with significantly severe hepatitis symptoms with a rapid elevation to above 30× the upper limit of normal at 4 days after fenofibrate initial treatment.
In most cases, documents from the online 'LiverTox' database demonstrated that elevated liver enzymes eventually declined to normal within 2 to 12 months after the discontinuation of fenofibrate. 1 Surprisingly, we found that the hypertriglyceridemia of the case was improved despite the short period of time of fenofibrate treatment; however, the plasma triglyceride concentrations re-elevated to previous levels after fenofibrate discontinuation in a one-month follow-up period (Table 1; Figure 1 ). On the other hand, the clinical symptoms and liver injury of the case rapidly recovered within two weeks of the withdrawal of fenofibrate, which was also helpful in confirming the diagnosis of fenofibrate-induced DILI.
The mechanism of DILI associated with fenofibrate is unclear thus far. The triglyceride-reducing effect of fenofibrate is thought to be mediated by the activation of the peroxisome proliferator-activated receptor α (PPARα) and lipoprotein lipase, which regulates the gene expression of enzymes involved in fatty acid oxidation and triglyceride clearance. 25 Furthermore, fenofibrate, a PPARα agonist, increases plasma and hepatic transaminase activities in parallel with increases in both ALT and AST gene expression via the PPARα pathway. 26, 27 This phenomenon was non-pathological and not considered to be a consequence of hepatotoxicity from fenofibrate. 17, [26] [27] [28] Obviously 
| WHAT IS NE W AND CON CLUS I ON
We report a case of fenofibrate-induced acute severe DILI with sudden onset and rapid recovery. As suggested, hepatic enzymes must be measures at least two weeks or even earlier after initial fenofibrate treatment followed by monitoring every 3 months within the first year of therapy. 18 We suggest that early detection of elevation of hepatic enzymes after fenofibrate initial treatment is important to avoid delayed diagnosis and subsequent treatment.
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